Lung Cancer,
Journal Year:
2021,
Volume and Issue:
157, P. 109 - 115
Published: May 13, 2021
Patients
with
cancer
may
be
at
increased
risk
of
more
severe
COVID-19
disease;
however,
prognostic
factors
are
not
yet
clearly
identified.
The
GRAVID
study
aimed
to
describe
clinical
characteristics,
outcomes,
and
predictors
poor
outcome
in
patients
lung
COVID-19.Prospective
observational
that
included
medical
records
PCR-confirmed
diagnosis
across
65
Spanish
hospitals.
primary
endpoint
was
all-cause
mortality;
secondary
endpoints
were
hospitalization
admission
intensive
care
units
(ICU).A
total
447
a
mean
age
67.1
±
9.8
years
analysed.
majority
men
(74.3
%)
current/former
smokers
(85.7
%).
NSCLC
the
most
frequent
type
(84.5
%),
mainly
as
adenocarcinoma
(51.0
stage
III
metastatic
or
unresectable
disease
(79.2
Nearly
60
%
receiving
anticancer
treatment,
mostly
first-line
chemotherapy.
Overall,
350
(78.3
hospitalized
for
13.4
11.4
days,
9
(2.0
admitted
ICU
146
(32.7
died.
Advanced
use
corticosteroids
treat
during
mortality.
Hospitalized,
non-end-of-life
lymphocytopenia
high
LDH
had
an
death.
Severity
correlated
higher
mortality,
admission,
mechanical
ventilation
rates.Mortality
rate
among
treated
hospitalization,
while
therapy
associated
Tailored
approaches
warranted
ensure
effective
management
minimizing
exposure
SARS-CoV-2.
Annals of Oncology,
Journal Year:
2021,
Volume and Issue:
32(6), P. 787 - 800
Published: March 20, 2021
Patients
with
cancer
may
be
at
high
risk
of
adverse
outcomes
from
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection.
We
analyzed
a
cohort
patients
and
2019
(COVID-19)
reported
to
the
COVID-19
Cancer
Consortium
(CCC19)
identify
prognostic
clinical
factors,
including
laboratory
measurements
anticancer
therapies.
active
or
historical
laboratory-confirmed
SARS-CoV-2
diagnosis
recorded
between
17
March
18
November
2020
were
included.
The
primary
outcome
was
severity
measured
on
an
ordinal
scale
(uncomplicated,
hospitalized,
admitted
intensive
care
unit,
mechanically
ventilated,
died
within
30
days).
Multivariable
regression
models
included
demographics,
status,
therapy
timing,
COVID-19-directed
therapies,
(among
hospitalized
patients).
A
total
4966
(median
age
66
years,
51%
female,
50%
non-Hispanic
white);
2872
(58%)
695
(14%)
died;
61%
had
that
present,
diagnosed,
treated
year
prior
diagnosis.
Older
age,
male
sex,
obesity,
cardiovascular
pulmonary
comorbidities,
renal
disease,
diabetes
mellitus,
black
race,
Hispanic
ethnicity,
worse
Eastern
Cooperative
Oncology
Group
performance
recent
cytotoxic
chemotherapy,
hematologic
malignancy
associated
higher
severity.
Among
patients,
low
absolute
lymphocyte
count;
neutrophil
platelet
abnormal
creatinine;
troponin;
lactate
dehydrogenase;
C-reactive
protein
diagnosed
early
in
pandemic
(January-April
2020)
than
those
later.
Specific
therapies
(e.g.
R-CHOP,
platinum
combined
etoposide,
DNA
methyltransferase
inhibitors)
30-day
all-cause
mortality.
Clinical
factors
older
hematological
malignancy,
chemotherapy)
poor
among
COVID-19.
Although
further
studies
are
needed,
caution
required
utilizing
particular
NCT04354701.
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: March 2, 2022
Infection
with
SARS-CoV-2,
the
causative
agent
of
Coronavirus
disease
2019
(COVID-19)
pandemic,
causes
respiratory
problems
and
multifaceted
organ
dysfunction.
A
crucial
mechanism
COVID-19
immunopathy
is
recruitment
activation
neutrophils
at
infection
site,
which
also
predicts
severity
poor
outcomes.
The
release
neutrophil
extracellular
traps
(NETs),
occurring
during
a
regulated
form
cell
death
known
as
NETosis,
key
effector
function
that
mediates
harmful
effects
caused
by
neutrophils.
Abundant
NETosis
NET
generation
have
been
observed
in
many
patients,
leading
to
unfavorable
coagulopathy
immunothrombosis.
Moreover,
excessive
are
now
more
widely
recognized
mediators
additional
pathophysiological
abnormalities
following
SARS-CoV-2
infection.
In
this
minireview,
we
introduce
subtypes
NET-producing
(e.g.,
low-density
granulocytes)
explain
biological
importance
NETs
protein
cargos
COVID-19.
addition,
discuss
mechanisms
upregulating
viral
processes
entry
replication)
well
host
pro-NET
proinflammatory
mediator
release,
platelet
activation,
autoantibody
production).
Furthermore,
provide
an
update
main
findings
immunothrombosis
other
COVID-19-related
disorders,
such
aberrant
immunity,
neurological
post
syndromes
including
lung
fibrosis,
disorder,
tumor
progression,
deteriorated
chronic
illness.
Finally,
address
potential
prospective
treatment
strategies
target
dysregulated
formation
via
inhibition
promotion
degradation,
respectively.
Journal for ImmunoTherapy of Cancer,
Journal Year:
2021,
Volume and Issue:
9(3), P. e002266 - e002266
Published: March 1, 2021
Cancer
patients
are
highly
vulnerable
to
SARS-CoV-2
infections
due
frequent
contacts
with
the
healthcare
system,
immunocompromised
state
from
cancer
or
its
therapies,
supportive
medications
such
as
steroids
and
most
importantly
their
advanced
age
comorbidities.
Patients
lung
have
consistently
been
reported
suffer
an
increased
risk
of
death
compared
other
cancers.
This
is
possibly
combination
specific
pathophysiological
aspects,
including
underlying
pulmonary
compromise
smoking
history
pressures
on
respiratory
services
caused
by
related
pandemic.
Rationally
safely
treating
during
pandemic
has
become
a
continuous
challenge
over
last
year.
Deciding
whether
offer,
modify,
postpone
even
cancel
treatments
for
this
particular
patient’s
population
crucial
recurrent
dilemma
professionals.
Chemotherapy,
immunotherapy
targeted
agents
represent
distinct
risks
factors
in
context
COVID-19
that
should
be
balanced
short-term
long-term
consequences
delaying
care.
Despite
rapid
persistent
trend
pandemic,
declared
WHO
March
11,
2020,
still
ongoing
at
time
writing
(January
2021),
various
efforts
were
made
oncologists
worldwide
understand
impact
cancer.
Adapted
recommendations
our
evidence-based
practice
guidelines
developed
all
stakeholders.
Different
small
large-scale
registries,
Consortium
(CCC19)
Thoracic
Cancers
International
Collaboration
quickly
collected
data,
supporting
care
decisions
under
challenging
circumstance
created
Several
guidance
prioritizing
aspects
order
mitigate
adverse
effects
crisis,
potentially
reducing
morbidity
mortality
These
helped
inform
about
treatment
established
disease,
continuation
clinical
research
screening.
In
review,
we
summarize
available
evidence
regarding
direct
indirect
patients.
Biomarker Research,
Journal Year:
2025,
Volume and Issue:
13(1)
Published: Jan. 6, 2025
Abstract
Background
and
objective
Esophageal
cancer
(EC)
is
the
seventh
most
prevalent
globally
sixth
leading
cause
of
cancer-related
mortality.
This
study
aimed
to
provide
an
updated
stratified
assessment
rates
in
EC
incidence,
mortality,
disability-adjusted
life-years
(DALYs)
from
1990
2021
by
sex,
age,
Socio-demographic
Index
(SDI)
at
global,
regional,
national
levels,
as
well
project
future
trends
both
regionally.
Methods
Data
about
age-standardized
(ASRs)
incidence
(ASIR),
mortality
(ASDR),
probability
death
(ASPoD)
DALYs
(ASDALYRs)
were
obtained
Global
Burden
Disease
(GBD)
study.
Estimated
annual
percentage
changes
(EAPCs)
average
(AAPC)
calculated
over
certain
periods
describe
temporal
burdens.
The
analyses
disaggregated
sexes,
GBD
super-regions
regions,
nations/territories,
age-groups,
SDI
quintiles.
A
Bayesian
age-period-cohort
(BAPC)
model
was
constructed
global
regional
ASRs
2022–2035.
Results
Despite
reductions
ASRs,
with
ASIR,
ASDR,
ASDALYR
6.65
[5.88,
7.45]
(95%
uncertainty
interval),
6.25
[5.53,
7.00],
148.56
[131.71,
166.82],
decreasing
24.9%,
30.7%,
36.9%
1990–2021,
respectively,
absolute
burden
numbers
increased
2021,
probably
because
population
growth
aging.
newly
diagnosed
cases,
deaths,
576,529
[509,492,
645,648],
356,263
[319,363,
390,154],
12,999,265
[11,522,861,
14,605,268]
62.53%,
51.18%,
33.28%
compared
records
1990.
geographical
pattern
consistent:
locations
highest
predominantly
located
Asian
Cancer
Belt
African
Corridor,
East
Asia,
Southern
Sub-Saharan
Africa,
Eastern
Africa
regions
heaviest
burdens,
Malawi,
Eswatini,
Mongolia,
Zambia,
Zimbabwe
2021.
However,
owing
size,
China,
India,
United
States,
Japan,
Brazil
had
More
pronounced
alleviations
observed
high
indicated
their
lower
AAPC
values
those
low-SDI
locations,
while
increasing
especially
Chad
(114.76%
for
example),
Sao
Tome
Principe
(97.93%),
Togo
(92.53%),
Northern
Mariana
Islands
(84.32%),
Liberia
(82.33%),
etc.
Smoking
remained
contributor
across
significantly
heavier
males,
males
being
2.89
2.88
times
higher,
than
females.
Across
all
age
groups,
posed
increasingly
significant
threat
men
aged
>
75
years.
From
2022
2035,
ASR
projections
show
only
modest
decrease
are
expected
increase
nearly
super-regions.
Conclusion
remains
significant,
disparities
regions.
Region-specific
age-targeted
measures
crucial
addressing
these
inequalities,
light
burdens
older
Efforts
should
be
taken
finding
more
solid
attributions
risk
factors
better
identify
high-risk
populations
inform
targeted
prevention
screening,
ultimately
reduce
efficient
cost-effective
way.
Graphical
